Effects of the gonadotropin-releasing hormone agonist [D-leu6, desgly-NH210, proethylamide9]-GnRH (leuprolide) on R3327-G rat prostatic tumor growth

Alan Pollack, Norman L Block, B. J. Stover, M. P. Fuentes, G. L. Irvin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The synthetic gonadotropin releasing hormone agonist [D-leu6, desgly-NH210, proethylamide9]-GnRH (leuprolide) was tested for its ability to inhibit androgen-sensitive R3327-G rat prostatic tumor growth in Copenhagen x Fischer F1 male rats. The chronic administration of leuprolide at 50 μg. per kg. body weight or 1000 μg. per kg. body weight significantly reduced serum testosterone levels and testis weights. Only chronic leuprolide administration at high concentration (100 μg. per kg.) compared with orchiectomy in reducing the rate of tumor growth, prolonging survival, and affecting changes in DNA content per cell as quantitated by flow cytometry. The DNA content changes and cell kinetic responses of R3327-G tumors to these treatments were related to the extent to which serum testosterone levels were reduced. The data suggest that for some prostatic cancers gonadotropin releasing hormone agonist administration must reduce serum testosterone levels to those achieved by orchiectomy for maximal growth rate inhibition.

Original languageEnglish
Pages (from-to)399-403
Number of pages5
JournalJournal of Urology
Volume131
Issue number2
StatePublished - Mar 22 1984
Externally publishedYes

Fingerprint

Leuprolide
Gonadotropin-Releasing Hormone
Testosterone
Orchiectomy
Growth
Serum
Body Weight
Neoplasms
DNA
Androgens
Testis
Prostatic Neoplasms
Flow Cytometry
Weights and Measures

ASJC Scopus subject areas

  • Urology

Cite this

Effects of the gonadotropin-releasing hormone agonist [D-leu6, desgly-NH210, proethylamide9]-GnRH (leuprolide) on R3327-G rat prostatic tumor growth. / Pollack, Alan; Block, Norman L; Stover, B. J.; Fuentes, M. P.; Irvin, G. L.

In: Journal of Urology, Vol. 131, No. 2, 22.03.1984, p. 399-403.

Research output: Contribution to journalArticle

@article{721e4807d8d24625bc84deaec6010fdd,
title = "Effects of the gonadotropin-releasing hormone agonist [D-leu6, desgly-NH210, proethylamide9]-GnRH (leuprolide) on R3327-G rat prostatic tumor growth",
abstract = "The synthetic gonadotropin releasing hormone agonist [D-leu6, desgly-NH210, proethylamide9]-GnRH (leuprolide) was tested for its ability to inhibit androgen-sensitive R3327-G rat prostatic tumor growth in Copenhagen x Fischer F1 male rats. The chronic administration of leuprolide at 50 μg. per kg. body weight or 1000 μg. per kg. body weight significantly reduced serum testosterone levels and testis weights. Only chronic leuprolide administration at high concentration (100 μg. per kg.) compared with orchiectomy in reducing the rate of tumor growth, prolonging survival, and affecting changes in DNA content per cell as quantitated by flow cytometry. The DNA content changes and cell kinetic responses of R3327-G tumors to these treatments were related to the extent to which serum testosterone levels were reduced. The data suggest that for some prostatic cancers gonadotropin releasing hormone agonist administration must reduce serum testosterone levels to those achieved by orchiectomy for maximal growth rate inhibition.",
author = "Alan Pollack and Block, {Norman L} and Stover, {B. J.} and Fuentes, {M. P.} and Irvin, {G. L.}",
year = "1984",
month = "3",
day = "22",
language = "English",
volume = "131",
pages = "399--403",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Effects of the gonadotropin-releasing hormone agonist [D-leu6, desgly-NH210, proethylamide9]-GnRH (leuprolide) on R3327-G rat prostatic tumor growth

AU - Pollack, Alan

AU - Block, Norman L

AU - Stover, B. J.

AU - Fuentes, M. P.

AU - Irvin, G. L.

PY - 1984/3/22

Y1 - 1984/3/22

N2 - The synthetic gonadotropin releasing hormone agonist [D-leu6, desgly-NH210, proethylamide9]-GnRH (leuprolide) was tested for its ability to inhibit androgen-sensitive R3327-G rat prostatic tumor growth in Copenhagen x Fischer F1 male rats. The chronic administration of leuprolide at 50 μg. per kg. body weight or 1000 μg. per kg. body weight significantly reduced serum testosterone levels and testis weights. Only chronic leuprolide administration at high concentration (100 μg. per kg.) compared with orchiectomy in reducing the rate of tumor growth, prolonging survival, and affecting changes in DNA content per cell as quantitated by flow cytometry. The DNA content changes and cell kinetic responses of R3327-G tumors to these treatments were related to the extent to which serum testosterone levels were reduced. The data suggest that for some prostatic cancers gonadotropin releasing hormone agonist administration must reduce serum testosterone levels to those achieved by orchiectomy for maximal growth rate inhibition.

AB - The synthetic gonadotropin releasing hormone agonist [D-leu6, desgly-NH210, proethylamide9]-GnRH (leuprolide) was tested for its ability to inhibit androgen-sensitive R3327-G rat prostatic tumor growth in Copenhagen x Fischer F1 male rats. The chronic administration of leuprolide at 50 μg. per kg. body weight or 1000 μg. per kg. body weight significantly reduced serum testosterone levels and testis weights. Only chronic leuprolide administration at high concentration (100 μg. per kg.) compared with orchiectomy in reducing the rate of tumor growth, prolonging survival, and affecting changes in DNA content per cell as quantitated by flow cytometry. The DNA content changes and cell kinetic responses of R3327-G tumors to these treatments were related to the extent to which serum testosterone levels were reduced. The data suggest that for some prostatic cancers gonadotropin releasing hormone agonist administration must reduce serum testosterone levels to those achieved by orchiectomy for maximal growth rate inhibition.

UR - http://www.scopus.com/inward/record.url?scp=0021323087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021323087&partnerID=8YFLogxK

M3 - Article

VL - 131

SP - 399

EP - 403

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -